Gastrointestinal-related adverse effects of COX-2 inhibitors

Drugs of Today

Volumn 39, Issue 12, 2003, Pages 939-948

  Foral, Pamela A ^a   Nystrom, Kelly K ^b   Wilson, Amy F ^b   Christensen, Carla M ^b  

^a CREIGHTON UNIVERSITY SCHOOL OF PHARMACY AND HEALTH PROFESSIONS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; LANSOPRAZOLE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; VALDECOXIB;

ABDOMINAL PAIN; CLINICAL TRIAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIGESTIVE SYSTEM ULCER; DISEASE SEVERITY; DRUG SAFETY; DRUG SELECTIVITY; DUODENUM PERFORATION; DYSPEPSIA; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; INFLAMMATION; INHIBITION KINETICS; META ANALYSIS; NAUSEA; OSTEOARTHRITIS; PAIN ASSESSMENT; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; STOMACH OBSTRUCTION; STOMACH PERFORATION; UPPER GASTROINTESTINAL BLEEDING;

CYCLOOXYGENASE INHIBITORS; DIGESTIVE SYSTEM; GASTROENTERITIS; HUMANS;

EID: 1642512313     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2003.39.12.799412     Document Type: Review

References (46)

1. Laine, L. Gastrointestinal safety of coxibs and outcomes studies: What's the verdict? J Pain Symptom Manage 2002, 23: S5-S10.
2. Giercksky, K.E., Haglund, U., Rask-Madsen, J. Selective inhibitors of COX-2 - Are they safe for the stomach? Scand J Gastroenterol 2000, 11: 1121-4.
3. Bjorkman, D.J. Commentary: Gastrointestinal safety of coxibs and outcomes studies: What's the verdict? J Pain Symptom Manage 2002, 23: S11-S14.
4. Wallace, J.L. Pathogenesis of NSAID-induced gastroduodenal mucosal injury. Best Pract Res Clin Gastroenterol 2001, 15: 691-703.
5. Halter, F., Schmassmann, A., Peskar, B.M. et al. Cyclooxygenase 2 - Implications on maintenance of gastric mucosal integrity and ulcer healing: Controversial issues and perspectives. Gut 2001, 49: 443-53.
6. Bidaut-Russell, M., Gabriel, S.E. Adverse gastrointestinal effects of NSAIDs: Consequences and costs. Best Pract Res Clin Gastroenterol 2001, 15: 739-53.
7. Peura, D.A. Gastrointestinal safety and tolerability of non-selective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors. Cleveland Clin J Med 2002, 69: S131-9.
8. Hawkey, C.J. COX-1 and COX-2 inhibitors. Best Pract Res Clin Gastroenterol 2001, 15: 801-20.
9. McCarthy, D.M. Prevention and treatment of gastrointestinal symptoms and complications due to NSAIDs. Best Pract Res Clin Gastroenterol 2001, 15: 755-73.
10. Lanza, F.L., Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. A Guideline for the Treatment and Prevention of NSAID-induced ulcers. Am J Gastroenterol 1998, 93: 2037-46.
11. Aalykke, C., Lauritsen, K. Epidemiology of NSAID-related gastroduodenal mucosal injury. Best Pract Res Clin Gastroenterol 2001, 15: 705-22.
12. Bombardier, C. An evidence-based evaluation of the gastrointestinal safety of coxibs. Am J Cardiol 2002, 89: 3D-9D.
13. Gabriel, S.E., Jaakkimainem, L., Bombardier, C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991, 115: 787-96.
14. Hernandez-Diaz, S., Rodriguez, L.A. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: An overview of epidemiology. Arch Intern Med 2000, 160: 2093-9.
15. Huang, J.Q., Lad, R.J., Sridhar, S. et. al. H. pylori infection increases the risk of ulceration. Gastroenterology 1999, 116: A192.
16. Goldstein, J.L., Correa, P., Zhao, W.W. et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naxopren in patients with arthritis. Am J Gastroenterol 2001, 96: 1019-27.
17. Silverstein, F.E., Faich, G., Goldstein, J.L. et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled trial. JAMA 2000, 284: 1247-55.
18. FDA Advisory Committee. Briefing Information: NDA 20-998/s009 celebrex (celecoxib), 2001. Available at: http://www.fda.gov. Accessed March 19, 2003.
19. Singh, G., Goldstein, J., Bensen, W. et al. SUCCESS-1 in osteoarthritis (OA) trial: Celecoxib significantly reduces risk of serious upper GI complications compared to NSAIDS while providing similar efficacy in 13,274 randomized patients. European League Against Rheumatism, Prague, Czech Republic, June 13-16, 2001 (Abstr.). Accessed from www.eular.org on March 17, 2003.
20. Goldstein, J., Eisen, G., Bensen, W. et al. SUCCESS in osteoarthritis (OA) trial: Celecoxib significantly reduces risk of upper gastrointestinal (UGI) hospitalizations compared to diclofenac and naproxen in 13,274 randomized patients with OA. European League Against Rheumatism, Prague, Czech Republic, June 13-16, 2001 (Abstr.). Accessed from www.eular.org on March 17, 2003.
21. Simon, L.S., Weaver, A.L., Graham, D.Y. et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. A randomized controlled trial. JAMA 1999, 282: 1921-8.
22. Deeks, J.J., Smith, L.A., Bradley, M.D. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: Systematic review of randomized controlled trials. Br Med J 2002, 325: 619.
23. Bombardier, C., Laine, L., Reicin, A. et al. The VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000, 343: 1520-8.
24. Gebal, G.P., Lisse, J.R., Perlman, M. et al. Gastrointestinal tolerability in primary care patients treated with naproxen or rofecoxib for osteoarthritis (OA): The ADVANTAGE Trial. European League Against Rheumatism, Prague, Czech Republic, June 13-16, 2001 (Abstract). Accessed from www.eular. org on March 17, 2003.
25. Makarowski, W., Zhao, W.W., Bevirt, T., Recker, D.P. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: A randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthr Cartil 2002, 10: 290-6.
26. Caroli, A., Monica, F. Severe upper gastrointestinal bleeding during treatment with rofecoxib for osteoarthritis. Am J Gastroenterol 2001, 96: 1663-4.
27. Freedman, G.M., Kreitzer, J.M., Ruchi, B. Rofecoxib-associated upper gastrointestinal bleed: A case report. Mt Sinai J Med 2002, 69: 105-6.
28. Foral, P.A., Wilson, A.F., Nystrom, K.K. Gastrointestinal bleeds associated with rofecoxib. Pharmacotherapy 2002, 22: 384-6.
29. Crawford, A.S., White, J.G. Celecoxib-induced upper gastrointestinal hemorrhage and ulceration. South Med J 2002, 95: 1444-6.
30. Bates, D.E., Lemaire, J.B. Possible celecoxib-induced gastroduodenal ulceration. Ann Pharmacother 2001, 35: 782-3.
31. Weaver, J., Bonnel, R.A., Karwoski, C.B., Brinker, A.D., Beitz, J. GI events leading to death in association with celecoxib and rofecoxib. Am J Gastroenterol 2001, 96: 3449-50.
32. Singh, G. Recent considerations in nonsteroidal anti-inflammatory gastropathy. Am J Med 1998, 105: 31S-38S.
33. Singh, G., Rosen-Ramey, D. NSAID induced gastrointestinal complications: The ARAMIS perspective - 1997. Arthritis, rheumatism and aging medical information system. J Rheum Suppl 1998, 51: 8-16.
34. Kendall, B.J., Peura, D.A.. NSAID-associated gastrointestinal damage and the elderly. GI disease in the elderly series: Article five in series. Pract Gastroenterol 1993, 17: 13-20, 29.
35. Fendrick, A.M. Cost-effective use of NSAIDs: Issues pertinent to coxib use in managed care. Am J Manag Care 2002, 8: S529-S541.
36. Retail and Provider Perspective, National Prescription Audit, 1999-2000. IMS Health, Plymouth, PA 2000.
37. Infoscan Services, Internal Analgesics Category, Total Food, Drug and Mass Merch, 52 weeks ending July 16, 2000. Information Resources, Inc., Plymouth, PA 2000.
38. Nonprescription Drugs USA 1999, Internal Analgesics Product Category. Kline and Company, Inc.: Little Falls, NJ 1999.
39. Hochberg, M.C. Treatment of rheumatoid and osteoarthritis with COX-2 selective inhibitors: A managed care perspective. Am J Manag Care 2002, 8: S502-S517.
40. Sturkenboom, M.C., Romano, F., Simon, G. et al. The iatrogenic costs of NSAID therapy: A population study. Arthritis Rheum 2002, 47: 132-40.
41. Raskin, J.B. Gastrointestinal effects of nonsteroidal anti-inflammatory therapy. Am J Med 1999, 106: 3S-12S.
42. Wolfe, F., Anderson, J., Burke, T.A., Arguelles, L.M., Pettitt, D. Gastroprotective therapy and risk of gastrointestinal ulcers: Risk reduction by COX-2 therapy. J Rheumatol 2002, 29: 467-73.
43. Laine, L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin N Am 1996, 6: 489-504.
44. Laine, L. Gastrointestinal effects of NSAIDs and coxibs. J Pain Symptom Manage 2003, 25S: S32-S40.
45. Singh, G., Triadafilopoulos, G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999, 26 (S56): 18-24.
46. Cantor, S.B. Pharmacoeconomics of coxib therapy. J Pain Symptom Manage 2002, 24: S28-S37.